Lakefront Biotherapeutics | GLPG - Current Liabilities


Lakefront Biotherapeutics reported EUR100.42M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
argenx SE USD 1.32B 278.28M Dec/2025
AstraZeneca USD 32.57B 1.95B Mar/2026
Biogen USD 3B 350.5M Mar/2026
Genmab DKK 1.43B 686M Dec/2025
Gilead Sciences USD 9.48B 2.34B Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
GRIFOLS EUR 2.12B 105M Mar/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Incyte USD 1.49B 25.52M Mar/2026
Merck EUR 9.35B 307M Mar/2026
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sanofi EUR 30.01B 1.66B Mar/2026
UCB EUR 4.4B 470M Dec/2025
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026